The annual JPMorgan Healthcare Conference, one of the largest healthcare industry events, kicks off this week in San Francisco. Major pharmaceutical and medical device companies have already announced a flurry of deals totaling $6.4 billion ahead of the high-profile conference.
Recent Notable Deals
Several prominent acquisitions took place on January 8th, as companies moved to reinforce key therapeutic areas before converging on San Francisco:
- Johnson & Johnson agreed to acquire the remaining stake in cardiovascular robotics firm Auris Health Inc for $3.4 billion
- Merck announced the purchase of cancer therapy biotech Seagen Inc for $2.7 billion
- Boston Scientific revealed plans to buy Axonics Modulation Technologies, a maker of implants to treat bladder issues, for $270 million
Earlier deals in the lead up to the conference include:
- Novartis obtaining Coherus BioSciences’ biosimilar assets for $760 million
- Bristol Myers Squibb acquiring Turning Point Therapeutics for $3.2 billion
This flurry of activity shows that dealmaking is rebounding after a relatively quiet 2023. Various factors are aligning to make acquisitions particularly attractive right now:
- Flush corporate balance sheets and hungry CEOs
- More reasonable biotech valuations
- Strong clinical trial data
- Supportive Federal policy environment
What to Expect at the Conference
The conference, running from January 9-12, is a pivotal event for the global healthcare industry. After going fully virtual in 2021 due to COVID-19, the event returned to San Francisco last year with around 9,000 attendees. This year, over 10,000 industry executives, investors, bankers, policymakers, and more will flock to the city.
With rising economic uncertainty, many attendees see the event setting the tone for 2024. Key themes and announcements to watch for include:
|Companies will highlight new therapies in major disease areas like cancer, immunology, neurology, and rare diseases. Vertex and Biomarin clinical readouts will draw particular interest. Obesity-focused firms will also share progress.
|Digital transformation will be another key theme, as tech giants showcase tools for data analytics, clinical trials, patient engagement and more.
|With uncertainty around election-year drug pricing reforms, executives will outline policy priorities and discuss strategies to navigate the volatile regulatory environment.
|On the heels of recent deals, speakers will predict where consolidation makes sense across pharma, biotech, devices, and services. Attendees will explore partnership opportunities.
The conference delivers a welcome boost to San Francisco’s economy, generating over $80 million in regional economic impact. Hotels, restaurants, transportation providers, and local vendors see significant revenue.
The city’s growing life sciences sector also seizes the moment to reinforce San Francisco’s stature as a biotech hub. Over 700 companies are based regionally, drawn by access to capital, talent, and research institutes. The JP Morgan conference spotlights local success stories, strengthening efforts to incubate more high-growth ventures.
The Road Ahead
Coming out of JP Morgan week, pharmaceutical and medtech leaders will turn their attention to executing key priorities over 2024:
- Integrating acquisitions – Companies will work to seamlessly onboard acquired capabilities and portfolios.
- Advancing pipelines – Critical clinical trials and regulatory submissions will continue for high-potential therapies.
- Pursuing more deals – The recent burst of deals could inspire other players to seek their own attractive biotech targets.
- Adapting to policy shifts – Executives will update government relations strategies based on the latest political developments.
- Capitalizing on innovation – Fresh ideas showcased at JP Morgan around AI, data science, gene editing and more will make their way into new R&D and digital health efforts.
The healthcare sector faces no shortage of complexity and uncertainty. However, the level of energy and wheeling-and-dealing at this year’s JP Morgan gathering suggests that leading companies are ready to tackle industry challenges head on. Expect the innovation on display in San Francisco this week to drive meaningful progress against patient needs over the coming year.
To err is human, but AI does it too. Whilst factual data is used in the production of these articles, the content is written entirely by AI. Double check any facts you intend to rely on with another source.